Elebsiran is under clinical development by Vir Biotechnology and currently in Phase II for Hepatitis D. According to GlobalData, Phase II drugs for Hepatitis D does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Elebsiran LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Elebsiran overview

Elebsiran (VIR-2218) is under development for the treatment of hepatitis B and D virus infections. It is administered through subcutaneous route and acts by targeting hepatitis B virus (HBV) genome including HBsAg. It is a siRNA therapeutic developed based on enhanced stabilization chemistry (ESC)-GalNAc-conjugate delivery platform technology.

Vir Biotechnology overview

Vir Biotechnology (Vir) is a biotechnology company which carries out the development of therapeutic products to prevent and treat serious infectious diseases. It develops treatments for viral and bacterial diseases and induce protective and therapeutic immune responses. The company includes in multi-program, multi-platform approach. Vir focuses on chronic infectious diseases including hepatitis B, tuberculosis, HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV) and metapneumovirus (MPV), healthcare-acquired infections. It has operations in Portland, Oregon, Boston, Massachusetts, Bellinzona, Switzerland. Vir is headquartered in San Francisco, California, the US.

For a complete picture of Elebsiran’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.